Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms
Christian Rothermundt, J Von Rappard, T Eisen, B Escudier, V Grünwald, J Larkin, D McDermott, J Oldenburg, C Porta, B Rini, M Schmidinger, C N Sternberg & Paul Martin Putora
MATERIALS AND METHODS
In contrast to the first-line setting, recommendations for second-line systemic treatment of mccRCC among experts were not as heterogeneous. The agents mostly used after disease progression on a first-line TKI included: EVE, AXI, NIV and sTKI. In the future setting of NIV and CAB availability, NIV was the most commonly chosen drug, whereas several experts identified situations where CAB would be preferred.
|citation||Rothermundt C, von Rappard J, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C N, Putora P M. Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World J Urol 2016;.|
|type||journal paper/review (English)|
|date of publishing||3-8-2016|
|journal title||World J Urol|